Recon: How Trump and RFK Jr. could reshape healthcare; Moderna reports slower RSV vaccine sales but better-than-expected COVID vaccine revenue
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- ‘MAHA’ is moving into Trump’s White House. Here’s who RFK Jr. could bring along for the ride (STAT)
- D.C. Diagnosis: RFK Jr. targets the F in FDA (STAT)
- RFK Jr. says ‘entire departments’ at FDA ‘have to go’ (The Hill) (MSNBC interview)
- Donald Trump returns to the presidency with big ambitions to shake up health care (STAT)
- Biotech and pharma executives on what Trump and RFK Jr. could mean for the industry (STAT) (MedTech Dive)
- FDA seeks to pull OTC nasal decongestant ingredient due to lack of efficacy (Endpoints)
- Moderna reports slow start to RSV sales as Bancel steps back from commercial role (Endpoints)
- Moderna reports surprise profit on higher-than-expected COVID vaccine sales (Reuters)
- AstraZeneca says China has detained a senior executive (STAT)
- Coherus restarts biosimilar supply after delays; Novavax ends Covid vaccine deal with UK (Endpoints)
- Africa health body calls on Trump to honour US vaccine pledges (Reuters)
- Whirlwind Week As German Medtechs Ponder Trump Effect And Whither Domestic Government (MedTech Insight)
- UK Diagnostic Services Must Get In Shape To Benefit From AI Opportunities (MedTech Insight)
- Sarepta discontinues next-generation Duchenne drugs (STAT)
- Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact (Endpoints)
- Denali teases early data for enzyme replacement therapy in rare disease (Endpoints)
- Xanax maker Viatris beats quarterly estimates on demand for new generic drugs (Reuters)
- Genmab chops early cancer prospects to prioritize Phase 3 projects (Endpoints)
- Aurinia cuts nearly half of its workforce in second round of layoffs this year (Endpoints)
- Geron’s royalty deal; Minghui’s new VEGF bispecific data (Endpoints)
- Grifols on track to meet 2024 targets as core earnings rise (Reuters)
- Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit (Fierce Pharma)
- AGC Biologics aims to become 'safe harbor' for manufacturing clients as new CEO takes the reins (Fierce Pharma)
- While Lilly Blames Wholesalers for Slow GLP-1 Sales, Novo’s Rival Medicine Is Flowing (BioSpace)
- Viracta Therapeutics Cuts 42% of Staff as Part of Resource Reprioritization (BioSpace)
- These 6 companies are using AI to streamline clinical trials for pharma (STAT)
- How Menlo Ventures thinks AI in health tech is going to be commoditized (Endpoints)
- US FDA approves Johnson & Johnson's device for heart condition (Reuters)
- Tempus AI to buy genetic testing company for $600M (MedTech Dive)
- Masimo, amid leadership transition, targets cost reductions (MedTech Dive)
- Advamed asks CMS to cover extra imaging of dense breast tissue (MedTech Dive)
- lucoModicum’s Magnetohydrodynamic CGM Platform Moves Closer To The Clinic (MedTech Insight)
- Social media misinformation is scaring women about birth control (STAT)
- Cover Supplemental Breast Screenings, AdvaMed Urges Medicare (MedTech Insight)
- While the Orphan Battles Wage, Jazz Takes a Loss (FDA Law Blog)
- Siemens Healthineers confident it can cope with Trump tariffs (MedTech Dive)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
